INS and metabolic dysfunction-associated steatotic liver disease: Abnormalities in the hepatic insulin signaling pathway not only disrupt glucose and lipid metabolism but are also closely linked to chronic low-grade inflammation, oxidative stress, and other mechanisms that drive the onset and progression of MASLD.